Screener
Cytek Biosciences, Inc. CTKB Business Segments — Amortization - license & IP expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept ctkb:AmortizationLicenseAndIPExpense.
The source filing: Cytek Biosciences, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053496
| (In thousands) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Service | 15,584 | 14,187 | 30,940 | 27,534 |
| Total revenue, net | $48,140 | $45,602 | $92,275 | $87,059 |
| Cost of sales (excluding stock-based compensation) | 18,584 | 20,144 | 40,255 | 39,865 |
| Amortization - license & IP expense | 481 | 481 | 962 | 974 |
| Sales (excluding stock-based compensation) | 9,042 | 7,832 | 17,855 | 16,438 |
| Marketing (excluding stock-based compensation) | 3,357 | 3,066 | 5,411 | 5,765 |
| Research and development (excluding stock-based compensation) | 8,649 | 7,403 | 17,290 | 15,551 |
| General and administrative (excluding stock-based compensation) | 14,088 | 10,509 | 30,166 | 20,644 |
Item 1. Consolidated Financial Statements (Unaudited)
FAQ
- What is Cytek Biosciences, Inc.'s business segments — amortization - license & IP expense?
- Cytek Biosciences, Inc. (CTKB) reported business segments — amortization - license & IP expense of $481K in Q2 2026.
- How has Cytek Biosciences, Inc.'s business segments — amortization - license & IP expense changed year-over-year?
- Cytek Biosciences, Inc.'s business segments — amortization - license & IP expense decreased by 0.0% year-over-year, from $481K to $481K.
- What is the long-term trend for Cytek Biosciences, Inc.'s business segments — amortization - license & IP expense?
- Over 3 years (2022 to 2025), Cytek Biosciences, Inc.'s business segments — amortization - license & IP expense has grown at a 17.8% compound annual growth rate (CAGR), from $1.18M to $1.94M.
- What does business segments — amortization - license & IP expense mean?
- Reflects the systematic allocation of the cost of intangible assets, such as licenses and intellectual property, over their useful lives. This non-cash expense highlights the capital investment required to maintain the segment's technological competitive advantage.
Ask your AI about Cytek Biosciences, Inc.'s business segments — amortization - license & ip expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude